Bill > HR4619

This bill, the Pharmaceutical REPAI Act (Pharmaceutical Rebates for Excessive Pricing Above Inflation Act), requires drug manufacturers to pay a Medicare Part D rebate for certain drugs if the price of those drugs increases faster than inflation. Specifically, the bill requires drug manufacturers, subject to civil penalties, to issue rebates to the Centers for Medicare & Medicaid Services (CMS) for covered drugs under the Medicare prescription drug benefit that cost $100 or more and for which the average manufacturer price increases faster than inflation. The rebate amount is based on the difference between the average manufacturer price and the inflation-adjusted payment amount for the drug.